AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
The Journal.
Trillion Dollar Shot, Episode 1: Birth of a Blockbuster
May 13, 2024
Meet Lotte Bjerre Knudsen, a young scientist at Novo Nordisk focusing on GLP-1 for diabetes treatment. Dive into the story of a breakthrough drug, Ozempic, and the race for a trillion-dollar market cap. Explore the impact of weight loss medications and the evolution of Simeglotide from diabetes treatment to weight loss solution.
40:51
Episode guests
AI Summary
Highlights
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- GLP-1 drugs like Ozempic were developed for diabetes but transitioned to obesity treatment, showcasing significant weight loss effects.
- The success of GLP-1 drugs has led to a booming market with societal impacts, but ethical concerns arise over high costs and off-label prescriptions for weight loss.
Deep dives
The Development of GLP-1 Drugs for Diabetes Treatment
The podcast delves into the story of how GLP-1 drugs, like Ozempic, were developed to treat diabetes. It follows the journey of the scientist Lauda Bier-Konutsen at Novo Nordisk in the 1990s as she worked on creating a compound mimicking the GLP-1 hormone. Despite setbacks, including tumorigenesis concerns in animal studies, the team eventually succeeded with a long-acting GLP-1 compound, leading to the approval of Liraglutide in 2010.
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode